Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips

Moderna shares are giving back a large portion of Tuesday’s rally, re-raising concerns about what a ~$59B market capitalization implies versus the company’s income statement. The article frames the pullback as a valuation-check following a summer “melt-up,” suggesting investors may be recalibrating expectations rather than reacting to a specific new fundamental catalyst.